YaleBreastCancer
@yalebreast
@yalecancer. Director @maryam_lustberg Co Director @greenuprachel Chief Research Directors @QinYan1 #LajosPusztai
ID: 1558949572801695749
14-08-2022 22:52:39
920 Tweet
1,1K Takipçi
1,1K Takip Edilen
T-DXd has shown tremendous activity in trials. But how does it perform in the real world? What is its activity in pts with BRCA+, PDL1+ dz, or prior SG? We joined forces with Yale University to address this question in one of the largest studies to date (n=~1500).🧵 esmoopen.com/article/S2059-…
It was a pleasure to talk to the team at Hello Bio about my somewhat atypical path, growing from undergrad to associate professor at the same university Yale Internal Medicine Yale Cancer Center (I did change labs at one point…but it was from my mentor’s to my own!)
Exciting Transdisciplinary Conference Organized by Dr. Muna Al-Khaifi and Team - Maryam Lustberg Maryam Lustberg MD, MPH, FASCO Dr.Muna Al-Khaifi MD.CCFP.MPH oncodaily.com/blog/maryam-lu… #Health #Oncology #OncoDaily #Medicine #Cancer CancerWorld
Help us fundraise for breast cancer research and program Yale Cancer Center #CTFRIDE rideclosertofree.org/team/7252
Oncologists have a unique responsibility to lead #survivorship care—from diagnosis through the 'seasons' of survival. In The Lancet Oncology, Maryam Lustberg MD, MPH, FASCO contends tailored, patient-centered models are essential to meet the growing + complex needs of #cancersurvivors.
How do different breast cancer treatments perform immediately after T-DXd? In our latest #JNCI paper, we analyzed data from ~800 pts with MBC in Flatiron, finding promising rwPFS with several regimens, yet some degree cross-resistance between T-DXd and SG. academic.oup.com/jnci/advance-a…
In metastatic #breastcancer, sacituzumab govitecan given after trastuzumab deruxtecan was linked to ⬇️ PFS across all subtypes. Real-world data published in JNCI show differences in outcomes by type. academic.oup.com/jnci/advance-a… Smilow Cancer Hospital YaleBreastCancer Maryam Lustberg MD, MPH, FASCO
Don't miss this research brief on the timing of recurrence after neoadjuvant chemo-immunotherapy in early-stage #TripleNegativeBreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40689866/ Luca Licata, MD Marco Mariani Rebecca Dent Sara Tolaney Erika Hamilton, MD, FASCO YaleBreastCancer Giampaolo Bianchini #BreastCancer #bcsm
CATE study open for enrollment at Yale Cancer Center and selected Translational Breast Cancer Research Consortium sites Contact us to learn more
An empowering & emotional day at our Caring for Metastatic Breast Cancer conference 💗 From groundbreaking research to personal stories of strength, we”re reminded: no one faces #MBC alone. #BreastFriendsFund Smilow Cancer Hospital YaleBreastCancer Maryam Lustberg MD, MPH, FASCO
Dr. Ian Krop presents today at #ESMO25 in a special symposium on unmet needs of patients with metastatic #breastcancer. #MBC cslide.ctimeetingtech.com/esmo2025/atten… Smilow Cancer Hospital YaleBreastCancer
💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management & so much more ✨Thank you Lynn Sage Breast Cancer Foundation for the travel award! 💐#LSBC25 Lurie Cancer Center Stephanie A. Haddad, DO Yale Hematology Oncology Fellows
Thank you to everyone that joined us Wednesday night at the Saybrook Point Resort & Marina for an evening of networking and connections around the topic of #womenshealth! Smilow Cancer Hospital Maryam Lustberg MD, MPH, FASCO Rachel Adams Greenup Tracy Battaglia
Could #GLP1s affect #breastcancer recurrence? Dr. Melinda Irwin explains to Oprah Daily how weight management can improve inflammation, metabolism, immune function + estrogen levels—factors linked to recurrence. oprahdaily.com/life/health/a6… Yale Cancer Center YaleBreastCancer The Breast Cancer Research Foundation Yale School of Public Health
